Clinical Trials Logo

Serious Systemic Infections clinical trials

View clinical trials related to Serious Systemic Infections.

Filter by:
  • None
  • Page 1

NCT ID: NCT01222585 Completed - Clinical trials for Necrotizing Enterocolitis

Metronidazole Pharmacokinetics (PK) in Premature Infants

PTN_METRO
Start date: January 2011
Phase: Phase 1
Study type: Interventional

Yearly in the United States over 500,000 newborns are delivered prematurely. This population is at high risk of catastrophic bowel disease known as necrotizing enterocolitis. Infants with necrotizing enterocolitis are at high risk of death, and survivors are at increased risk of mental retardation. Metronidazole is an antibiotic that is often administered to infants with suspected or confirmed necrotizing enterocolitis. Unfortunately, the appropriate dose of metronidazole in premature infants has not been established and it is likely to be different from older children and adults. The investigators will investigate the appropriate metronidazole dose in very premature infants by: 1) determining how premature infants eliminate metronidazole from the body and 2) determining the safest and most effective dose of metronidazole in premature infants. The investigators hypothesis are: 1) The rate of removal of metronidazole will increase with infant maturity and 2) an appropriate metronidazole dosing regimen will result in necessary drug levels to treat bacteria involved in necrotizing enterocolitis.